中国人类蛋白质组计划(CNHPP)正式启动

2014-06-17 佚名 仪器信息网

今天上午,“中国人类蛋白质组计划(CNHPP)”在军事医学科学院召开第一次工作部署会,国家 科技部、总后勤部相关领导、重点专项管理委员会成员及全国40多个科研单位的70余名院士、专家出席,这标志着CNHPP全面启动实施,这是我国科学界乃至世界生命科学领域一件具有里程碑意义的大事。)这项计划,在国际注明期刊Science上也做出了相关报道:Science:中国将大量资金投入蛋白质组

今天上午,“中国人类蛋白质组计划(CNHPP)”在军事医学科学院召开第一次工作部署会,国家
科技部、总后勤部相关领导、重点专项管理委员会成员及全国40多个科研单位的70余名院士、专家出席,这标志着CNHPP全面启动实施,这是我国科学界乃至世界生命科学领域一件具有里程碑意义的大事。)这项计划,在国际注明期刊Science上也做出了相关报道:Science:中国将大量资金投入蛋白质组研究 

人类蛋白质组计划(HPP)是继基因组计划之后人类全面探索自我奥秘征程中又一伟大科技工程,是新世纪第一个国际大型科技合作计划。在国家科技部等部门的大力支持下,中国科学家率先倡导并领衔了人类第一个器官(肝脏)国际蛋白质组计划(HLPP),开中国引领国际大型科技合作计划之先河,所形成的理论框架、整体策略和技术标准被国际同行广泛认可和应用,为人类蛋白质组计划的全面展开发挥了示范和指导作用,得到学术界高度评价。

中国科学家构建了人类第一个器官(肝脏)蛋白质组图谱,出版人类首个器官蛋白质组“百科全书”,相关数据得到国际著名专业机构等认同及广泛使用,成为人类蛋白质百科全书主体内容之一,部分工作被《自然》杂志最近发表的人类蛋白质组草图的文章引用。近4年,中国在该领域国际核心刊物发文量直线上升,历史性地达到1000多篇,跃居世界第二。在新的代谢通路调控、炎症诱发肿瘤、骨形成调节、疾病易感性等方面取得系列原创成果,相关论文发表在《科学》、《自然》等国际一流刊物,并被国际同行评述为重大突破性进展。总体来说,我国蛋白质组学研究已处于国际先进水平。

亚太蛋白质组组织主席、该计划首席科学家贺福初院士介绍说,CNHPP是在系统总结HLPP成功经验基础上,经过4年迭代论证提出的,主要目标是以我国重大疾病的防治需求为牵引,发展蛋白质组研究相关设备及关键技术,绘制人类蛋白质组生理和病理精细图谱、构建人类蛋白质组“百科全书”,全景式揭示生命奥秘,为提高重大疾病防诊治水平提供有效手段,为我国生物医药产业发展提供原动力。这是我国863高技术计划、973基础研究计划、国际合作计划再次联手资助的重点专项,也是国家大科学设施与大科学计划的首次会师,将在我国开创大科学设施、大科学计划、大数据产出、大发现孕育的新时代。

当前,全球每年产生的生物数据总量高达EB级,生命科学领域正在爆发一次数据革命。据统计,2000 年以来,国际上共发表2万余篇有关高通量生物数据的文献;近几年,《自然-遗传》近三分之一的论文是介绍关于高通量生物数据的工作。数据已成为矿物或化学元素一样的原始材料,未来可能形成“数据探矿”、“数据化学”等新学科和“数据驱动”的新模式,孕育着科学大发现、大突破和产业大发展的前所未有的重大机遇。

大数据的产生、管理和利用正逐步成为衡量一个国家创新能力以及竞争力的关键要素。但目前生物大数据的产生和分析还被美国、欧洲、日本等少数国家所垄断。我国生物数据主权受到严重威胁。从过去来看,生物数据最大的是基因组数据,基因组计划实施和完成后,蛋白质组数据无疑将成为最大、最重要和最核心的科学数据。我国已部署建设蛋白质科学基础设施,这是国际上最大的蛋白质组学研究基地,将有力支撑和推动CNHPP的实施和大数据的产生,有望迅速改变现有格局,打破垄断,维护国家生物数据主权。

CNHPP产生的大数据将全景式地揭示人体蛋白质组成及其调控规律,解读人类基因组这部“天书”。构建的人类蛋白质组生理和病理图谱,将呈现多种病理状态下蛋白质组的变化,揭示疾病的发病机制和病理过程,发现系列新型诊断标志物、治疗靶点和创新药物,为全面提高疾病防诊治水平提供新策略新手段。

最近英国《自然》杂志同时刊登两篇文章,介绍了美国和德国、印度等合作完成的人类蛋白质组草图的工作。中国科学院院士饶子和说,这是蛋白质组学领域乃至整个生命科学领域和人类科技史上具有里程碑意义的一项重要科学贡献,拉开了新一轮科技竞赛的序幕。中国科学院院士张玉奎指出,逆水行舟不进则退,中国科学家在这场新世纪最重要、最核心和最具代表性的大数据资源争夺中没有犹豫的时间,没有回头的道路,只有勇往直前,直面竞争的选择。我们必须充分发挥体制优势,借鉴“两弹一星”、“载人航天”等国家重大工程实施的成功经验,集中力量,重点突破,打赢这场没有硝烟的科技竞赛和资源争夺战。

贺福初院士表示,在人类基因组计划中,中国作为六国中唯一的发展中国家,做出了1%的贡献,2001年,江泽民总书记与美英等国首脑共同宣布了人类基因组草图的问世;在人类蛋白质组计划中,中国作为第二大经济体和复兴崛起的大国,将做出不少于30%的贡献,并有望成为最大的贡献国。我们梦想在2017年,习近平总书记可以代表主要完成国宣布人类蛋白质组精细图的问世。我们将为实现这一梦想而不懈努力!中国必须为人类做出更大贡献!中国必然为人类做出更大贡献!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=54775, encodeId=ed3b54e7525, content=又一个里程碑工程, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Jan 09 09:27:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079874, encodeId=248220e987420, content=<a href='/topic/show?id=f39349263c' target=_blank style='color:#2F92EE;'>#CNHPP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4926, encryptionId=f39349263c, topicName=CNHPP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Mon Apr 27 00:11:00 CST 2015, time=2015-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754805, encodeId=4d901e54805cf, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Fri Dec 19 06:11:00 CST 2014, time=2014-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765524, encodeId=85161e65524ce, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon May 18 11:11:00 CST 2015, time=2015-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296887, encodeId=5f16129688e0e, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jun 19 01:11:00 CST 2014, time=2014-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9964, encodeId=79949964ae, content=贺福初又折腾了,也不知道忽悠了多少钱哦。, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dingning, createdTime=Tue Jun 17 14:53:00 CST 2014, time=2014-06-17, status=1, ipAttribution=)]
    2016-01-09 lyh994

    又一个里程碑工程

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=54775, encodeId=ed3b54e7525, content=又一个里程碑工程, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Jan 09 09:27:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079874, encodeId=248220e987420, content=<a href='/topic/show?id=f39349263c' target=_blank style='color:#2F92EE;'>#CNHPP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4926, encryptionId=f39349263c, topicName=CNHPP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Mon Apr 27 00:11:00 CST 2015, time=2015-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754805, encodeId=4d901e54805cf, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Fri Dec 19 06:11:00 CST 2014, time=2014-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765524, encodeId=85161e65524ce, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon May 18 11:11:00 CST 2015, time=2015-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296887, encodeId=5f16129688e0e, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jun 19 01:11:00 CST 2014, time=2014-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9964, encodeId=79949964ae, content=贺福初又折腾了,也不知道忽悠了多少钱哦。, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dingning, createdTime=Tue Jun 17 14:53:00 CST 2014, time=2014-06-17, status=1, ipAttribution=)]
    2015-04-27 sodoo
  3. [GetPortalCommentsPageByObjectIdResponse(id=54775, encodeId=ed3b54e7525, content=又一个里程碑工程, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Jan 09 09:27:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079874, encodeId=248220e987420, content=<a href='/topic/show?id=f39349263c' target=_blank style='color:#2F92EE;'>#CNHPP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4926, encryptionId=f39349263c, topicName=CNHPP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Mon Apr 27 00:11:00 CST 2015, time=2015-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754805, encodeId=4d901e54805cf, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Fri Dec 19 06:11:00 CST 2014, time=2014-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765524, encodeId=85161e65524ce, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon May 18 11:11:00 CST 2015, time=2015-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296887, encodeId=5f16129688e0e, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jun 19 01:11:00 CST 2014, time=2014-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9964, encodeId=79949964ae, content=贺福初又折腾了,也不知道忽悠了多少钱哦。, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dingning, createdTime=Tue Jun 17 14:53:00 CST 2014, time=2014-06-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=54775, encodeId=ed3b54e7525, content=又一个里程碑工程, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Jan 09 09:27:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079874, encodeId=248220e987420, content=<a href='/topic/show?id=f39349263c' target=_blank style='color:#2F92EE;'>#CNHPP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4926, encryptionId=f39349263c, topicName=CNHPP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Mon Apr 27 00:11:00 CST 2015, time=2015-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754805, encodeId=4d901e54805cf, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Fri Dec 19 06:11:00 CST 2014, time=2014-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765524, encodeId=85161e65524ce, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon May 18 11:11:00 CST 2015, time=2015-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296887, encodeId=5f16129688e0e, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jun 19 01:11:00 CST 2014, time=2014-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9964, encodeId=79949964ae, content=贺福初又折腾了,也不知道忽悠了多少钱哦。, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dingning, createdTime=Tue Jun 17 14:53:00 CST 2014, time=2014-06-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=54775, encodeId=ed3b54e7525, content=又一个里程碑工程, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Jan 09 09:27:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079874, encodeId=248220e987420, content=<a href='/topic/show?id=f39349263c' target=_blank style='color:#2F92EE;'>#CNHPP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4926, encryptionId=f39349263c, topicName=CNHPP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Mon Apr 27 00:11:00 CST 2015, time=2015-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754805, encodeId=4d901e54805cf, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Fri Dec 19 06:11:00 CST 2014, time=2014-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765524, encodeId=85161e65524ce, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon May 18 11:11:00 CST 2015, time=2015-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296887, encodeId=5f16129688e0e, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jun 19 01:11:00 CST 2014, time=2014-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9964, encodeId=79949964ae, content=贺福初又折腾了,也不知道忽悠了多少钱哦。, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dingning, createdTime=Tue Jun 17 14:53:00 CST 2014, time=2014-06-17, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=54775, encodeId=ed3b54e7525, content=又一个里程碑工程, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Jan 09 09:27:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079874, encodeId=248220e987420, content=<a href='/topic/show?id=f39349263c' target=_blank style='color:#2F92EE;'>#CNHPP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4926, encryptionId=f39349263c, topicName=CNHPP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Mon Apr 27 00:11:00 CST 2015, time=2015-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754805, encodeId=4d901e54805cf, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Fri Dec 19 06:11:00 CST 2014, time=2014-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765524, encodeId=85161e65524ce, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon May 18 11:11:00 CST 2015, time=2015-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296887, encodeId=5f16129688e0e, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jun 19 01:11:00 CST 2014, time=2014-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9964, encodeId=79949964ae, content=贺福初又折腾了,也不知道忽悠了多少钱哦。, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=dingning, createdTime=Tue Jun 17 14:53:00 CST 2014, time=2014-06-17, status=1, ipAttribution=)]
    2014-06-17 dingning

    贺福初又折腾了,也不知道忽悠了多少钱哦。

    0

相关资讯

综述:抑郁症的蛋白质组学研究进展

    抑郁症是一类高患病率、高致残率、高致死率的精神疾病,严重影响人类身心健康。然而其病理机制尚不清楚,亟需对抑郁症的病因开展新的研究。抑郁症的生物学发生是一个极其复杂的过程,涉及多种蛋白质表达的变化及由此引起的生物化学反应和信号传导的改变,要了解抑郁症的分子机制,须揭示细胞内和细胞间各种蛋白的结构和功能变化。既往研究多局限于探讨一个或几个蛋白质的变化,这些研究结果

Nature:人类蛋白质组草图里程碑成果发布

两个独立研究小组绘制了人体组织和细胞系质谱分析图谱,公布了近乎完整的人类蛋白质组草图。日前,两个国际小组均在《自然》杂志上公布了人类蛋白质组第一张草图,这些在大部分非患病人体组织和器官中表达的精选蛋白,为更好的理解疾病状态下发生的机体变化,奠定了坚实的基础。这两项最新研究揭示了人类基因组的更多复杂性,并从之前认为属于非编码区域的基因组中发现了新蛋白。波士顿儿童医院蛋白质组学主任Hanno St